

Fan Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/151026/publications.pdf>

Version: 2024-02-01

19
papers

388
citations

759233

12
h-index

794594

19
g-index

22
all docs

22
docs citations

22
times ranked

599
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell-Mediated Antitumor Activity. <i>Frontiers in Immunology</i> , 2022, 13, 845193.	4.8	16
2	Silencing of long non-coding RNA FOXD2-AS1 inhibits the progression of gallbladder cancer by mediating methylation of MLH1. <i>Gene Therapy</i> , 2021, 28, 306-318.	4.5	11
3	Long noncoding RNA LEF1-AS1 acts as a microRNA regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 86-99.	2.6	20
4	The imbalance of biliary microflora in hepatolithiasis. <i>Microbial Pathogenesis</i> , 2021, 157, 104966.	2.9	5
5	microRNA-485-5p inhibits the progression of hepatocellular carcinoma through blocking the WBP2/Wnt signaling pathway. <i>Cellular Signalling</i> , 2020, 66, 109466.	3.6	25
6	Circular RNA MYLK Promotes Hepatocellular Carcinoma Progression Through the miR29a/KMT5C Signaling Pathway. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8615-8627.	2.0	12
7	LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7. <i>Cell Cycle</i> , 2020, 19, 870-883.	2.6	16
8	Long noncoding RNA LINC00324 exerts protumorigenic effects on liver cancer stem cells by upregulating fas ligand via PU box binding protein. <i>FASEB Journal</i> , 2020, 34, 5800-5817.	0.5	29
9	Upregulated microRNA194 impairs stemness of cholangiocarcinoma cells through the Rho pathway via inhibition of ECT2. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 4239-4250.	2.6	15
10	Long noncoding LINC01551 promotes hepatocellular carcinoma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of microRNA122-5p to regulate ADAM10 expression. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 16393-16407.	2.6	25
11	Long noncoding RNA LINC00488 functions as a ceRNA to regulate hepatocellular carcinoma cell growth and angiogenesis through miR-330-5. <i>Digestive and Liver Disease</i> , 2019, 51, 1050-1059.	0.9	23
12	Expression of KLF9 in pancreatic cancer and its effects on the invasion, migration, apoptosis, cell cycle distribution, and proliferation of pancreatic cancer cell lines. <i>Oncology Reports</i> , 2018, 40, 3852-3860.	2.6	23
13	Bleeding risk in cancer patients treated with sorafenib: A meta-analysis of randomized controlled trials. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 948.	0.9	7
14	Overexpression of non-SMC condensin I complex subunit G serves as a promising prognostic marker and therapeutic target for hepatocellular carcinoma. <i>International Journal of Molecular Medicine</i> , 2017, 40, 731-738.	4.0	42
15	Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 824-832.	3.4	47
16	Inhibitory effect of humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles conjugate on growth of human hepatocellular carcinoma: in vitro and in vivo studies. <i>Asian Pacific Journal of Tropical Medicine</i> , 2014, 7, 337-343.	0.8	10
17	Laparoscopic hepatectomy is associated with a higher incident frequency in hepatolithiasis patients. <i>Surgery Today</i> , 2013, 43, 1371-1381.	1.5	14
18	Risk of Serious Neutropenic Events in Cancer Patients Treated with Bevacizumab: A Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 2453-2459.	1.2	6

#	ARTICLE	IF	CITATIONS
19	Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1879-1890.	2.5	16